Supportive care

Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. Marn Pernat A et al. Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432. Effective Removal of x03BA;-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings. Jayaballa M et al. Blood Purif. 2016 Jun 8;42(2):158-159. [Epub ahead of print]. Thirteen treatment…

Details

Complications of myeloma and its treatments

Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. Chalayer E et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24454. [Epub ahead of print]. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Karrasch…

Details

Current treatments

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Hulin C et al.J Clin Oncol. 2016 Jun 20. pii: JCO667295. [Epub ahead of print]. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following…

Details

Diagnostic tests and prognostic indicators

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Terpos E et al. Blood Cancer J. 2016 May 27;6:e428. doi: 10.1038/bcj.2016.37. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Bhatti S et al. Eur Heart J Cardiovasc Imaging. 2016 May 25. pii: jew101. [Epub…

Details

Related conditions

The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. Cao XX et al. Leuk Res. 2016 May 4;46:85-88. doi: 10.1016/j.leukres.2016.05.002. [Epub ahead of print]. Rare and unusual clinicopathologic presentation of renal AL amyloidosis. Logan A et al. JRSM Open. 2016 May 3;7(5):2054270416640156. doi: 10.1177/2054270416640156. eCollection 2016. Diagnosis, risk stratification and management of monoclonal gammopathy of…

Details

Emerging treatments

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Moreau P et al.Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Tandon N et al. Clin Pharmacol. 2016 May 6;8:35-44. doi: 10.2147/CPAA.S94021. eCollection 2016. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Usmani SZ et…

Details

Biology and genetics

Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Song Y et al. Leukemia. 2016 May 20. doi: 10.1038/leu.2016.97. [Epub ahead of print]. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Krejcik J et al. Blood. 2016 May 24. pii: blood-2015-12-687749. [Epub ahead of print]. Unusual cytological features in multiple myeloma. Abdulsalam AH et al. Am J Hematol. 2016 May 24.…

Details